{
    "root": "2f9c1aab-e0d4-c04e-e063-6294a90ab24c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paroxetine",
    "value": "20250305",
    "ingredients": [
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
            "code": "X2ELS050D8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7936"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        }
    ],
    "indications": {
        "text": "paroxetine tablets indicated adults treatment : \u2022 major depressive disorder ( mdd ) \u2022 obsessive compulsive disorder ( ocd ) \u2022 panic disorder ( pd ) \u2022 social anxiety disorder ( sad ) \u2022 generalized anxiety disorder ( gad ) \u2022 posttraumatic stress disorder ( ptsd )",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "obsessive compulsive disorder (DOID:10933)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10933"
            },
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 recommended starting maximum daily mdd , ocd , pd , ptsd : ( 2.2 ) indication starting daily dose maximum daily dose mdd 20 mg 50 mg 0cd 20 mg 60 mg pd 10 mg 60 mg ptsd 20 mg 50 mg \u2022 recommended starting sad gad 20 mg daily . ( 2.3 ) \u2022 elderly patients , patients severe renal impairment severe hepatic impairment : starting 10 mg daily . maximum 40 mg daily . ( 2.4 ) \u2022 discontinuing paroxetine tablets , reduce gradually . ( 2.6 , 5.7 )",
        "doid_entities": [
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "paroxetine tablets usp , 10 mg white off-white , round-shaped , biconvex , film- coated tablets debossed logo 'zc , 15 bisect ' one side plain side , supplied follows : boxes 10x10 ud 100 ndc 63739-888-10 paroxetine tablets usp , 20 mg white off-white , round-shaped , biconvex , film- coated tablets debossed logo 'zc , 16 bisect ' one side plain side , supplied follows : boxes 10x10 ud 100 ndc 63739-963-10 storage store 20\u00b0 25\u00b0 c ( 68\u00b0 77\u00b0 f ) [ usp controlled room temperature ] .",
    "adverseReactions": "paroxetine tablets contraindicated patients : \u2022 taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7 ) ] . \u2022 taking thioridazine risk qt prolongation [ ( 5.3 ) ( 7 ) ] \u2022 taking pimozide risk qt prolongation [ ( 5.3 ) , ( 7 ) ] . \u2022 known hypersensitivity ( e.g . , anaphylaxis , angioedema , stevens-johnson syndrome ) paroxetine inactive ingredients paroxetine tablets [ ( 6.1 ) , ( 6.2 ) ] .",
    "indications_original": "Paroxetine tablets are indicated in adults for the treatment of:\n  \n\u2022 Major depressive disorder (MDD)\n  \n\u2022 Obsessive compulsive disorder (OCD)\n  \n\u2022 Panic disorder (PD)\n  \n\u2022 Social anxiety disorder (SAD)\n  \n\u2022 Generalized anxiety disorder (GAD)\n  \n\u2022 Posttraumatic stress disorder (PTSD)",
    "contraindications_original": "\u2022 Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: (2.2) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg 0CD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg \u2022 Recommended starting dosage for SAD and GAD is 20 mg daily. (2.3) \u2022 Elderly patients, patients with severe renal impairment or severe hepatic impairment: Starting dosage is 10 mg daily. Maximum dosage is 40 mg daily. (2.4) \u2022 When discontinuing paroxetine tablets, reduce dosage gradually. (2.6, 5.7)",
    "warningsAndPrecautions_original": "Paroxetine Tablets USP, 10 mg are white to off-white, round-shaped, biconvex, film- coated tablets debossed with the logo of 'ZC, 15 and bisect' on one side and plain on other side, and are supplied as follows:\n                  \n                     \nBoxes of 10x10 UD 100 NDC 63739-888-10\n \n                  \n                     \nParoxetine Tablets USP, 20 mg are white to off-white, round-shaped, biconvex, film- coated tablets debossed with the logo of 'ZC, 16 and bisect' on one side and plain on other side, and are supplied as follows:\n \n                  \n                     \nBoxes of 10x10 UD 100 NDC 63739-963-10\n \n                  \n                     \n                     Storage\n                  \n                  \n                     \nStore at 20\u00b0 to 25\u00b0 C (68\u00b0 to 77\u00b0 F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Paroxetine tablets are contraindicated in patients:\n  \n\u2022 Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see\n  \nWarnings and Precautions (5.2), Drug Interactions (7)].\n  \n\u2022 Taking thioridazine because of risk of QT prolongation [see Warnings and Precautions (5.3) and Drug Interactions (7)]\n  \n\u2022 Taking pimozide because of risk of QT prolongation [see Warnings and Precautions (5.3), Drug Interactions (7)].\n  \n\u2022 With known hypersensitivity (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome) to paroxetine or any of the inactive ingredients in paroxetine tablets [see\n  \nAdverse Reactions (6.1), (6.2)].",
    "drug": [
        {
            "name": "Paroxetine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7936"
        }
    ]
}